Eli Lilly and Company
Explore Eli Lilly and
Core profile pages, annual revenue records, and related research hubs for this company.
Eli Lilly and Company
Explore Eli Lilly and
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 1876 in Indianapolis, Indiana
Colonel Eli Lilly founded the company in Indianapolis in 1876 with a focus on producing reliable medicines at industrial scale. That manufacturing and research orientation remains central to the company.
Colonel Eli Lilly founds the company in Indianapolis.
Lilly helps commercialize insulin at industrial scale, shaping its long-term diabetes identity.
The company expands through antibiotics and broader prescription medicines.
Lilly introduces Humulin, one of the first recombinant DNA human insulin products.
David A. Ricks becomes Chair, President, and CEO.
Mounjaro receives U.S. approval for type 2 diabetes, beginning a major growth cycle.
Zepbound receives U.S. approval for chronic weight management.
Lilly reports $65.179B in 2025 revenue and $20.640B in net income.
Lilly acquired Loxo Oncology in January 2019 for approximately $8 billion to acquire a precision oncology platform built around the concept of targeting specific genomic alterations in cancer regardless of tumor type. Loxo had pioneered the development of highly selective kinase inhibitors designed to minimize off-target effects while achieving exceptional on-target potency against genomically defined cancer populations. The acquisition was intended to accelerate Lilly's transformation into a precision medicine oncology leader at a time when the company recognized that undifferentiated cytotoxic chemotherapy partnerships were not a sustainable competitive strategy in oncology.
Lilly acquired Morphic Therapeutic in August 2024 for approximately $3.2 billion to access the company's integrin inhibitor platform, which includes MORF-057, an oral small-molecule inhibitor of α4β7 integrin with potential in inflammatory bowel disease including Crohn's disease and ulcerative colitis. The inflammatory bowel disease market represents a high-value segment that Lilly had not previously addressed with differentiated proprietary assets, and Morphic's oral small-molecule approach offered a potential advantage over existing large-molecule biologics like vedolizumab that require infusion or injection. The acquisition reflected Lilly's strategy of using its strong balance sheet and cash generation to acquire late-stage development assets that can be accelerated through its global clinical and commercial infrastructure.
Lilly acquired POINT Biopharma Global Inc. In October 2023 for approximately $1.4 billion to acquire the company's radioligand therapy (RLT) platform and manufacturing infrastructure. Radioligand therapies, which combine tumor-targeting molecules with radioactive isotopes to deliver targeted radiation to cancer cells, represent a rapidly advancing area of oncology following the commercial success of Novartis's Lutathera and Pluvicto. The acquisition gave Lilly access to POINT's proprietary radiopharmaceutical manufacturing facilities—a specialized industrial capability that is scarce globally—as well as a pipeline of RLT candidates in clinical development for prostate cancer and other malignancies.
Lilly acquired Prevail Therapeutics in January 2021 for approximately $1.04 billion upfront plus contingent payments to access the company's gene therapy platform targeting neurological diseases, particularly Parkinson's disease and related alpha-synucleinopathies. Prevail's lead asset, PR001, is an AAV9-based gene therapy designed to deliver a functional copy of the GBA1 gene to neurons, targeting the subset of Parkinson's disease patients with GBA1 mutations who face faster disease progression. The acquisition represented Lilly's first significant investment in the gene therapy space and reflected the company's strategy of expanding its neuroscience portfolio beyond small molecules and antibodies.
The company was founded in May 1876 in Indianapolis, Indiana.
It was founded by Colonel Eli Lilly, a highly decorated veteran of the American Civil War and a highly trained pharmaceutical chemist.
In the 1870s, medicine was incredibly dangerous. 'Snake oil' salesmen sold massive amounts of highly toxic, unregulated elixirs. Colonel Lilly founded his company with the absolute mandate that he would only produce highly precise, scientifically proven prescription medicines for doctors.
Insulin. In 1923, diabetes was a total death sentence. Researchers at the University of Toronto discovered insulin but couldn't manufacture it. Eli Lilly partnered with them and became the absolute first company in history to mass-produce pure insulin (Iletin), saving millions of lives globally.
Yes. In 1986, Eli Lilly launched Prozac (fluoxetine). It was a massive, historic breakthrough in treating clinical depression with vastly fewer side effects than older drugs. It became an absolute cultural phenomenon and the highest-selling drug in the world.